151 results about "Traitement adjuvant" patented technology

A prerequisite for clinical vaccines is the construction of safe and highly immunogenic reagents able to generate efficient immune responses against target antigens. Lipid based delivery vesicles, including virosomes, as clinically approved safe vaccines, can be used to elicit both humoral and cell-mediated responses against protein antigens and mediate effective immune responses against the target pathogen and / or induce tumor rejection. Thus the compositions of the present invention are useful either as a primary vaccination or as a boost in combination with other vaccines in a context of an adjuvant treatment plan.

The invention relates to a glycopeptide mixture product and application thereof in preparing a medicament for improving the nutritional status and immunologic function of tumor patients receiving radiotherapy and chemotherapy and health food or food. A glycopeptide mixture is prepared by mixing marine oligopeptide and bioactive polysaccharide according to certain proportion. The marine oligopeptide is a group of oligopeptide mixtures with low molecular weights which are produced by taking fish skin, fish meat or fish bone of marine fishes as main raw materials through enzymatic hydrolysis, can be dissolved by trichloroacetic acid, and have relative molecular mass less than 1,000, and has the characteristics of easy absorption, quick absorption, low viscosity, good water solubility, and the like. The bioactive polysaccharide comprises lentinan, ganoderan, grifola polysaccharide, panaxan, lycium bararum polysaccharide and algal polysaccharide. Animal experiments and clinical observation prove that the glycopeptide mixture prepared by mixing the marine oligopeptide and the bioactive polysaccharide has the effect of improving the immunologic function of tumor-bearing mice and the nutritional status of the tumor patients receiving radiotherapy and chemotherapy.

Predicting response to adjuvant therapy or predicting disease progression in breast cancer is realized by (1) first obtaining a breast cancer test sample from a subject; (2) second obtaining clinicopathological data from said breast cancer test sample; (3) analyzing the obtained breast cancer test sample for presence or amount of (a) one or more molecular markers of hormone receptor status, one or more growth factor receptor markers, (b) one or more tumor suppression / apoptosis molecular markers; and (c) one or more additional molecular markers both proteomic and non-proteomic that are indicative of breast cancer disease processes; and then (4) correlating (a) the presence or amount of said molecular markers and, with (b) clinicopathological data from said tissue sample other than the molecular markers of breast cancer disease processes. A kit of (1) a panel of antibodies; (2) one or more gene amplification assays; (3) first reagents to assist said antibodies with binding to tumor samples; (4) second reagents to assist in determining gene amplification; permits, when applied to a breast cancer patient's tumor tissue sample, (A) permits observation, and determination, of a numerical level of expression of each individual antibody, and gene amplification; whereupon (B) a computer algorithm, residing on a computer can calculate a prediction of treatment outcome for a specific treatment for breast cancer, or future risk of breast cancer progression.

The invention discloses a preparation method for the dendritic cell (DC) of an umbilical cord blood source and a dendritic cell (DC) vaccine, which relates to a preparation method for the dendritic cell. According to the method, various cell factors are adopted to induce DC obtained by umbilical cord blood separation, and then the DC is stimulated by a tumor specific antigen so as to improve the specific antigen presentation capability of the DC; and a stem cell growth factor and Flt3-L are added into a cell culture medium so as to effectively accelerate a hematopoietic cell in the umbilical cord blood to induce and proliferate to an immune cell. The DC vaccine prepared with the method has the specific antigen presentation capability, can be combined with a CIK (cytokine induced killer) cell to mutually treat the malignant tumor when being used as a tumor immunotherapy product, and is used as an important adjuvant therapy after operations and chemoradiotherapy. Recurrence and metastasis after the operations can be effectively prevented, and toxic and side effects caused by the chemoradiotherapy on patients are lowered so as to improve the treatment effect.

The invention relates to a pseudomonas aeruginosa mutant strain genetic engineering mutant strain, in particular to a pseudomonas aeruginosa mutant strain exotoxin A attenuated strain, and further relates to a preparation method of the mutant strain and application of the mutant strain or the attenuated strain in preparing vaccines or adjuvant therapy drugs.

The invention provides a cervical cancer postoperative survival prediction method, system and device and a medium, and belongs to the technical field of medicine. On the basis of traditional patient evaluation, the influence of pathological factors on postoperative survival of patients is emphasized, and on the basis of a machine learning algorithm, a clinical prediction model for predicting postoperative survival of early cervical cancer patients is developed. According to the invention, more personalized clinical guidance opinions can be provided for selection and accurate treatment of earlycervical cancer postoperative adjuvant therapy schemes, so that the method has good practical application value.

The invention discloses a composite capable of preventing bacteria, viruses, oxidation and pigment deposition, which is characterized by being prepared from the following raw materials in proportion by weight: 0.1-10 of epigallocatechin gallate (EGCG), 0-10 of chlorogenic acid, 0-10 of asiaticoside and 0-10 of ginkgolide. The invention also discloses application of the composite in preparing drugs, health-care food and cosmetics, which are capable of preventing bacteria, viruses, oxidation and pigment deposition. The composite of the invention has favorable safety, is suitable for curing respiratory tract infection, condyloma acuminatum, herpes progenitalis, chromatosis and other diseases, simultaneously has anti-oxidation and skin whitening functions, protects cells and DNA from being damaged, can prevent and cure dementia and chloasma, and also can be used for cancer adjuvant therapy.

The invention discloses a medicine for treating cardiocerebrovascular diseases, which is mainly prepared by the following raw materials: coenzyme Q10 (CoQ10), Vitamin E (VE) and soybean lecithin (PC). The medicine is widely used for treating coronary heart disease, cardiac failure, arrhythmia, rheumatic heart disease, viral myocarditis, blood supply deficiency, high blood pressure, and other cardiocerebrovascular diseases and periodontitis resulted from gingival atrophy and also can be used as adjuvant therapy for acute and chronic viral hepatitis and cancer, which also has the efficacies of decreasing blood lipid, lowering cholesterol, regulating internal secretion, eliminating climacteric syndrome, resisting aging, preventing senile dementia, etc. In addition, the invention also discloses a production method for preparing the medicine for treating cardiocerebrovascular diseases with semisynthetic raw material.

The invention discloses cell inactivated vaccine which simultaneously contains porcine circovirus epitopes and goose circovirus epitopes. The cell inactivated vaccine is prepared by the method including screening high-pathogenicity strains from porcine circoviruses; selecting a plurality of virus epitopes; connecting the epitopes with one another; then inserting the connected epitopes into genomes of goose circoviruses to proliferate; and adding Freund adjuvants to formaldehyde for inactivation so as to obtain the cell inactivated vaccine. The invention simultaneously discloses an egg yolk antibody prepared from the cell inactivated vaccine, injection and freeze-dried powder containing the egg yolk antibody. Genes of the porcine circovirus are inserted into the genomes of the goose circoviruses, the immunogenicity of the goose circoviruses is strengthened, immune systems of goose bodies are excited, so that the titer of generated antibodies is higher than that of egg yolk antibodies generated by porcine circovirus vaccine used singularly, a clinical application effect is good, and generated circovirus antibodies have an auxiliary treatment effect for porcine circovirus diseases.

The invention discloses a method for preparing ice cream by adopting camel milk. According to the method disclosed by the invention, the camel milk or camel milk powder is used as the main raw material, then the raw materials such as honey, poria cocos, Chinese yam and sodium caseinate are added, a special raw material extraction technology is adopted, and the prepared ice cream is low in energy, high in protein content and low in fat content; meanwhile, due to the combined action of all raw materials, an adjuvant therapy effect on hyperlipidemia, hypertension, chronic pharyngitis, prostate disease, fatty liver and tumor radio-chemotherapy is obtained, congestive heart failure can also be relieved, coughs can be relieved, the kidney can be protected, negative conversion of hepatitis B is facilitated, and the immunity can be greatly enhanced.

The invention relates to a pharmaceutical composition for adjuvant therapy of cancers and a preparation method thereof. The pharmaceutical composition of the invention comprises the following traditional Chinese medicine raw material herbs: radix astragali, gen-seng, radix codonopsis, bighead atractylodes rhizome, poria cocos, sculellaria barbata, oldenlandia diffusa, glaucescent fissistigma roots, scorpion, centipede, radices trichosanthis, rhizoma sparganii, curcuma zedoary, licorice, and the like, has the efficacy of breaking blood, removing blood stasis, softening hardness and dissipating binds, is applicable to adjuvant therapy of various cancers, and has significant curative effect after years of clinical application.

The invention provides a biodegradable poly-HPMA-Gd magnetic resonance imaging (MRI) probe used for inserting enzyme sensitive polypeptide GFLG into a poly-HPMA backbone structure. The molecular weight of a prepared polymer is basically controllable, the molecular weight is high, and the dispersion coefficient (PDI) is low; and linear HPMA-DOTA-Gd is obtained through coupling with Gd(III). The probe is an efficient nanoscale MRI probe with biocompatibility, and can be used for clinical tumor diagnosis and adjuvant therapy.

The invention discloses an anti-novel coronavirus antibody. The antibody is a high-titer specific antibody extracted from chicken egg yolk, the chicken egg yolk is mainly obtained from eggs laid by immunized hens, and the immunized hens are healthy hens injected with novel coronavirus vaccines. The invention also discloses an adjuvant drug for preventing and controlling the novel coronavirus, which takes the antibody for resisting the novel coronavirus as a main component. The drug exerts the characteristics of the antibody for resisting the novel coronavirus, can be specifically combined withthe novel coronavirus of the oropharynx and the nasal cavity in a short time, is long in retention time, painless, non-irritant, good in safety performance and free of toxic and side effects, can beused for prevention and blocking of novel coronavirus infection and adjuvant therapy of early infection, and can be used for group virus prevention and control adjuvant medication.

The invention relates to the technical field of molecular biology, and in particular relates to a recombinant protein, a protein compound containing the recombinant protein and application. The recombinant protein disclosed by the invention is composed of a human interleukin 1 receptor antagonist protein and a protein containing a VPGKG repetitive unit, can be used for adjuvant therapy of rheumatoid arthritis, acute gouty arthritis and other rheumatic immune diseases, hereditary diseases and tumours with increased interleukin 1 (interleukin, IL-1), and has a remarkable curative effect.

Acquired and de novo endocrine resistance are major clinical problems in the management of breast cancer patients. Though the antiestrogen tamoxifen prolongs disease-free and overall survival in the adjuvant setting, and induces remissions in over half of the patients with estrogen receptor positive metastatic disease, all patients eventually acquire tamoxifen resistance. Furthermore, many of the resistant tumors actually appear to be stimulated by tamoxifen just as they are by estrogens. The present invention provides methods of predicting endocrine resistance comprising detecting the biological activity and / or expression of p38 MAPK and / or AIB1. The invention further provides methods of reducing, reversing, or preventing endocrine resistance comprising contacting a breast or prostate tumor with a p38 MAPK pathway inhibitor.

The invention discloses a method for efficient in-vitro amplification and culture of natural killer T cells with high killing capacity. The method comprises the following steps: a, taking fresh human peripheral blood and obtaining mononuclear cells with a gradient centrifugation method; b, pre-stimulating mononuclear cells in an in vitro medium; c, expanding culture of peripheral blood derived mononuclear cells, detecting the proportion of various cells, and judging amplification efficiency and activity of the target NK / NKT cells; d, detecting the proportion of NK / NKT cells to the cell population after culture for 3-4 weeks, and detecting cell killing efficiency; e, further purifying the NK / NKT cells. The method is simple to operate, the NK cell population rich in NKT cells with high killing activity is obtained and contains no impurity cells, immunogenicity caused by the impurity cells is avoided, and side effects in clinical application are lower. Besides, the method has the advantages that materials are easily available, the cells are suitable for large-scale culture, damage to the body is small and the like, and is more suitable for adjuvant treatment of tumor patients.

Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.

The invention discloses an application of a traditional Chinese medicine composition in preparation of drugs for adjuvant therapy of novel coronavirus pneumonia. The traditional Chinese medicine composition comprises the raw materials: radix puerariae, radix scutellariae, rhizoma coptidis and radix glycyrrhizae preparata. Pneumonia patients infected by novel coronavirus mainly show fever, cough, dyspnea and the like, and part of the pneumonia patients can also show digestive system symptoms such as poor appetite, nausea, emesis, diarrhea and the like. Clinical experiments find that the traditional Chinese medicine composition has a good adjuvant therapy effect on novel coronavirus pneumonia in combination with conventional therapy, can quickly stabilize the condition of an illness, and particularly has a more obvious effect on improving cough, chest distress, nausea, vomiting, loose stool and the like. The average antipyretic time is 3 days, the average nucleic acid negative conversiontime is 8 days, and the clinical cure rate is 100%. The traditional Chinese medicine composition disclosed by the invention can block the conversion of mild and common pneumonia patients into severeand critical pneumonia patients; clinical symptoms of patients can be actively improved; lung inflammatory absorption can be well promoted; safe and reliable use is achieved.

Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.

The invention relates to a macromolecular hydrophilic gel and a preparation method and application thereof. The gel is made of Carbomer mixed with purified water, glycerinum and polysorbate, the pH value is adjusted by using sodium hydroxide solution, and the gel with negative electricity is prepared. The macromolecular hydrophilic gel has irregular bubbles, no stimulation and no other macroscopicexogenous impurities, and is transparent, in a viscous colloid shape and free from extraneous odor, the pH value is equal to 6.30-9.37, the dynamic viscosity is 5000-7000 mPa s, the microbial contentis 10 cfu / g, the total effective rate for allergic rhinitis patients in a clinical test can reach about 90%, and the effective rate of an on-sale congeneric product Mobijing as a control group is nomore than 70%; it is shown that compared with the congeneric product, the macromolecular hydrophilic gel can cure allergic rhinitis better, and has a good preventive and adjuvant therapeutic effects on the allergic rhinitis.

The invention relates to the technical field of medicines, and provides applications of uterine cavity fluid-derived exosome in preparation of drugs and adjuvant therapeutic agents for treating infertility related diseases. Through the verification of experiments, exosome realizes the treatment or relieving of endometrial growth disorders by promoting the increasing of the thickness of endometrium, enhancing the activity of endometrial cells, reducing the damages to intimal cells, promoting VEGF expression, maintaining the dryness of endometrial stromal cells and stimulating proliferation; andthrough the realizing of the treating or relieving of maternal-fetal immune tolerance disorder-related diseases by achieving immune tolerance effects, treating spontaneous abortion and enhancing T helper lymphocyte levels, a novel theoretical basis can be provided for infertility treatment. In addition, for both fertilized eggs being fertilized in vivo or fertilized in vitro, the exosome can effectively enhance developmental rates in multiples; and implantation rates and farrowing rates of in vitro fertilization transplantation can be increased as well, so that positive auxiliary effects on infertility treatment can be achieved.

This invention relates to precursor albumen that can generate multiple kinds effective contents through cutting. Stable and high efficiency expression of the precursor albumen in colibacillus genetic engineering can be got by this invention. Extra high efficiency bioactivity effective constituent albumen is got after the expressed precursor albumen is cut. It can be used as accessory cure of cancer.

The invention relates to a method for establishing a prediction model for survival benefit of a gallbladder cancer patient after chemoradiotherapy. The method comprises the steps of acquiring clinical and pathological data of the gallbladder cancer patient; dividing the acquired data into a plurality of groups of data according to the TNM stages, and respectively judging whether the patient in each stage is benefited from adjuvant therapy or not; dividing the data corresponding to the TNM stages into a modeling group and an internal verification group; analyzing the prediction capability of clinical and pathological variables of the modeling group data on the total survival time OS through a single-factor COX risk scale model, and screening risk factors which significantly influence the total survival time OS of the patient in the modeling group; incorporating the screened risk factors into a multi-factor COX risk scale model for analysis, and screening out influence variables significantly influencing the total survival time OS of the patient; according to the obtained influence variables, drawing a column graph used for predicting the total survival time OS, and obtaining a prediction model; and verifying the model. Compared with the prior art, the method has the advantages of providing credible prediction and analysis results for the GBC patient, being simple and convenient to operate and the like.

The invention belongs to the technical field of medicines, and particularly relates to an anti-cancer drug composition and an application thereof. The composition is a broad-spectrum anti-cancer agent and has therapy or adjuvant therapy functions for various cancers.

The invention discloses an early NSCLC prognosis prediction system, which comprises a main effect identification module, an interaction identification module, a survival time prediction module and a high-dimensional population discrimination module, and can improve the model prediction precision from the perspective of cross-omics by establishing a sample database and molecular biomarkers-methylation and gene expression. Different from a traditional biomarker, the system is stable and minimally invasive, the sensitivity and specificity of prognosis prediction are greatly improved, the main effect, GxE and GxG interaction effects are integrated, an early-stage NSCLC survival prediction model which is high in prediction precision and has strict multi-stage independent crowd verification is constructed, the defect that an existing model is poor in prediction effect is overcome, and a high-risk crowd discrimination module is combined. People with different risks are discriminated, diseaseprognosis is evaluated scientifically and accurately, and clinicians are helped to make clinical decisions or guide adjuvant therapy, early intervention and early benefit.

The invention belongs to the field of biological medicines, and particularly relates to a primer probe system and kit capable of simultaneously detecting multiple drug-resistant genes. Firstly, the invention discloses the primer system capable of simultaneously detecting multiple drug-resistant genes, and the primer system comprises a nucleotide sequence group with nucleotide sequences shown in SEQ ID NO: 1-24. The invention also discloses the kit comprising the primer system, and a method for detecting drug-resistant genes by using the primer system or the kit. The kit disclosed by the invention supports high-throughput detection, and can rapidly and accurately detect five bacterial drug-resistant genes with ultrahigh sensitivity, rapidly monitor the change of specific drug-resistant genes in a blood flow infection patient in real time according to quantitative / semi-quantitative detection results of the target drug-resistant genes, timely evaluate the condition of the patient, and provide adjuvant therapy suggestions for clinicians.

The invention belongs to the field of medicine and chemical industry, and relates to an anticancer application of a sterols derivative. The sterols derivative is a compound shown as the formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is selected form -OH, =O, H and C1-C3 alkyl; R2 is selected form -OH, H and C1-C3 alkyl; R3 is selected form -OH, =O, H and C1-C3 alkyl; R4 is selected form -OH, H and C1-C3 alkyl; and any two, three or four of R1, R2, R3 and R4 are -OH simultaneously. The compound provided by the invention is capable of effectively inhibiting proliferation of cancer cells (tumor cells), and the inhibition effect is in concentration-effect relationships, thus the sterols derivative has the potential of a medicament for prevention and / or treatment and / or adjuvant treatment of cancers.

The invention relates to a blood filtering and dialyzing system capable of filtering and separating CTCs of a human body from circulation blood of the human body. The blood filtering and dialyzing system serves as an adjuvant therapy device and is suitable for breast cancer patients with the positive CTCs. The blood filtering and dialyzing system is characterized in that in a pipe channel of an existing blood filtering and dialyzing device, a filter composed of biological membranes 8 micrometers in hole diameter is additionally arranged. The filter is a cylinder and taper double-layer barrel, and the blood dialyzing instrument artery end is communicated with an inner layer, wherein the inlet radius is r, and the inner layer is composed of biological membranes 8 micrometers in hole diameter; the blood dialyzing instrument vein end is communicated with an outer layer, and the outer layer is made of medical plastic. According to the filter, the heights of a cylinder in the inner layer and a cylinder in the outer layer are equal, the length is controllable in the scope ranging from 10 cm to 20 cm, the inner diameter is 4.472 r, the outer diameter is 4.48 r, the height of an inner taper is 4.472 r, the height of an outer tapper is 4.48 r, and the membrane hole distribution density is 100000 / cm<2>.

The invention relates to a recombinant bifidobacterium hRV-VP7 expression vector and the oral vaccine. The invention pertains to the field of genetic engineering. The technical problem to be solved is to construct a new bifidobacterium expression vector of hRV virus VP7 protein. The recombinant bifidobacterium hRV-VP7 expression vector of the invention is loaded with a virus protein VP7 coding gene sequence of a human group A rotavirus. The expression vector of the invention can be transfected into the bifidobacterium and can be further prepared into an hRV / VP7 transgenic bifidobacterium-hRV-VP7 recombinant vector oral live vaccine preparation after fermentation culture. The invention is mainly used for the prevention and adjuvant treatment of infantile diarrhea which is caused by human rotavirus, thus having great market prospect.

Antibodies to SEB, fragments thereof, and compositions comprising such are provided. Therapies for staphylococcal infection are provided, as well as assays for identifying additional agents useful in such therapies. An isolated antibody, or an isolated antigen-binding fragment of an antibody, is provided which antibody or antigen-binding fragment binds to staphylococcal enterotoxin B (SEB) and which antibody or antigen-binding fragment comprises a heavy chain variable CDR3 comprising the sequence RIYYGNNGGVMDY (SEQ ID NO:30); ARTAGLLAPMDY (SEQ ID NO:31); ARDTMRKCYCELKLKPPAEHPGPA (SEQ ID NO:32) or VRDL YGDYVGRY A Y (SEQ ID NO:48).